Mount Sinai Researchers Help Create Largest Immune Cell Atlas of Bone Marrow in Multiple Myeloma Patients
On Jan. 9, 2026, scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research…
-
-
Flu season surged in the U.S. over the holiday and already rivals last winter’s harsh epidemic
On Jan. 5, 2026, U.S. flu infections surged over the holidays, and health officials are calling it a…
-
CRISPR primes goldenberry for fruit bowl fame
On Dec. 19, 2025, Cold Spring Harbor Laboratory (CSHL) plant biologists may have found a “shortcut” to this…
-
Adaptive Inks deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases woth $890 Million
On Dec. 15, 2025, Adaptive Biotechnologies announced it has signed two non-exclusive deals with Pfizer to support research…
-
Race, Ethnicity and Donor Type Continue to Affect Survival After Donor Stem Cell Transplant
On Dec. 8, 2025, a study led by Roswell Park Comprehensive Cancer Center reveals that a patient’s race…
-
Artificial Intelligence | Biotechnology | Medical Device | Medicine | Nanotechnology | Neurology | Non-Profit Research | Pharmaceutical | Therapeutics
University at Buffalo to receive $50 million for biofabrication and imaging research hub
On Nov. 25, 2025, Governor Kathy Hochul announced the University at Buffalo (UB) will receive $50 million from…
-
Neural implant smaller than salt grain wirelessly tracks brain
On Nov. 3, 2025, Cornell researchers and collaborators have developed a neural implant so small that it can…
-
Blackstone, and TPG announce plans to take medtech Hologic private for $18.3 billion
On Oct. 21, 2025, private equity firms Blackstone and TPG said they will buy medical diagnostics firm Hologic…
-
The Jackson Laboratory acquires New York Stem Cell Foundation to transform biomedical research and accelerate precision therapies for patients
On Oct. 20, 2025, The Jackson Laboratory (JAX), a global leader in genetics and genomic medicine, announced it…
-
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
On Sept. 30, 2025, Pfizer announced an agreement with the White House that will ensure U.S. patients pay…
-
Final Landmark Clinical Trial Data Demonstrates Deep, Durable Responses to Menin Inhibition in Acute Leukemia Patients
On Sept. 25, 2025, final data from a landmark clinical trial in patients with an aggressive form of…
-
Variational AI Enters $349 Million Collaboration with Merck to Apply Generative AI to Drug Discovery
On Sept. 23, 2025, Variational AI a generative AI drug discovery company, announced a collaboration with Merck to…
-
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio for $4.9 billion
On Sept. 22, 2025, Pfizer and Metsera announced the companies have entered into a definitive agreement under which…
-
Novartis to acquire Tourmaline Bio and pipeline for atherosclerotic cardiovascular disease, valued at $1.4 Billion
On Sept. 9, 2025, Novartis announced that it has entered into an agreement to acquire Tourmaline Bio, a…
-
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
On Sept. 8, 2025, Pfizer and BioNTech announced positive topline results from an ongoing Phase 3 clinical trial…
-
Study Led by Roswell Park Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes
On Sept. 8, 2025, research led by Sai Yendamuri, MD, MBA, FACS, Chair of Thoracic Surgery at Roswell…
-
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64
On Aug. 27, 2025, Pfizer and BioNTech announced the U.S. Food and Drug Administration (FDA) has approved the…
-
AbbVie to Acquire Gilgamesh Pharma’s Investigational Therapy for Major Depressive Disorder for $1.2 Billion
On Aug. 25, 2025, AbbVie and Gilgamesh Pharmaceuticals announced a definitive agreement under which AbbVie will acquire Gilgamesh’s…
-
Artificial Intelligence | Biotechnology | Diagnostics | Non-Profit Research | Oncology | Therapeutics
CPRIT Approves $27 Million In Grants for Cancer Research in Texas
On Aug. 20, 2025, The Cancer Prevention and Research Institute of Texas (CPRIT) announced the approval of 15…
-
5th death linked to Legionnaires’ disease outbreak that has sickened dozens in New York City
On Aug. 19, 2025, health officials have uncovered another death in connection with a Legionnaires’ disease outbreak in…
-
4th person dies after a Legionnaires’ disease outbreak sickens dozens in New York City
On Aug. 14, 2025, a fourth person has died in connection with a Legionnaires’ disease outbreak in New…
-
New York City Health Department Provides Update on Community Cluster of Legionnaires’ Disease in Central Harlem
On Aug. 6, 2025, the New York City Health Department provided an update on the investigation into a…
-
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
On Jul. 25, 2025, Pfizer and BioNTech announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products…
-
New York City Health Department Investigated a Community Cluster of Legionnaires’ Disease in Central Harlem Neighborhood
On Jul. 25, 2025, the New York City Health Department (Health Department) announced an investigation into a community…
-
Experimental Compound Offers Potential Treatment for Rare, Often Fatal, Childhood Disease
On Jul. 9, 2025, as part of a new study, neurologists at NYU Langone Health announced they have…
-
World Microbiome Day Celebrated
On Jun. 27, 2025, today is World Microbiome Day and the Microbiota Vault, together with all participating Local…
-
Biotechnology | Disease | FDA | Medicine | Therapeutics
Dupixent approved in the U.S. as the only targeted medicine to treat patients with bullous pemphigoid
On Jun. 20, 2025, the US Food and Drug Administration (FDA) announced it has approved Dupixent (dupilumab) for…
-
BrainStorm Announces New Survival Data from Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn
On Jun. 16, 2025, BrainStorm Cell Therapeutics announced new survival data from 10 participants in its Expanded Access…
-
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
On May 30, 2025, Pfizer announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER…
-
Study Finds Cotton Virus Circulated Undetected for Nearly 20 years
On May 29, 2025, a virus responsible for damaging cotton crops across the southern United States has been…
